Biomarin Pharmaceutical: Q3 Earnings Insights
Biomarin Pharmaceutical (NASDAQ:BMRN) reported its Q3 earnings results on Wednesday, October 27, 2021 at 04:05 PM.
Here's what investors need to know about the announcement.
Biomarin Pharmaceutical Q3 EPS $(0.20) Beats $(0.25) Estimate, Sales $408.70M Miss $435.32M Estimate
Biomarin Pharmaceutical (NASDAQ:BMRN) reported quarterly losses of $(0.20) per share which beat the analyst consensus estimate of $(0.25) by 20 percent. This is a 104.99 percent decrease over earnings of $4.01 per share
Earnings Scheduled For October 27, 2021
Companies Reporting Before The Bell
• McDonald's (NYSE:MCD) is expected to report quarterly earnings at $2.46 per share on revenue of $6.03 billion.
The Week Ahead In Biotech (Oct. 24-30): Eyenovia, ANI Pharma, Clearside Medical FDA Decisions, Merck, Bristol-Myers Squibb Earnings, IPOs And More
Biotech stocks posted gains for the second week running, supported by multiple catalysts that included a good start to the big pharma reporting season and broader market strength.
Barron’s Latest Picks And Pans: Amazon, Apple, Chevron, Citigroup, Dell And More
This weekend's Barron's cover story features the latest results of the annual Barron's Big Money Poll.
Stifel Upgrades This Pharma Stock On Prospective FDA Approval For Dwarfism Drug
Stifel has upgraded BioMarin Pharmaceutical Inc’s (NASDAQ:BMRN) to Buy from Hold with a price target of $96, up from $86. After…
Stifel Upgrades Biomarin Pharmaceutical to Buy, Raises Price Target to $96
Stifel analyst Paul Matteis upgrades Biomarin Pharmaceutical (NASDAQ:BMRN) from Hold to Buy and raises the price target from $86 to $96.
